Treatment Selection in Acute Necrotizing Encephalopathy
In acute necrotizing encephalitis (ANE), start with high-dose methylprednisolone (30 mg/kg/day) combined with tocilizumab within 24 hours of symptom onset for high-risk patients (ANE severity score ≥5), while IVIG or PLEX should be reserved as second-line options or used in combination with steroids for lower-risk cases. 1, 2, 3
Risk Stratification First
Before selecting therapy, calculate the ANE severity score (ANE-SS):
- Low to medium risk (ANE-SS <5): 20-30 mg/kg/day methylprednisolone is effective 1
- High risk (ANE-SS ≥5): Requires aggressive combination therapy with 30 mg/kg/day methylprednisolone PLUS tocilizumab 1
Primary Treatment Algorithm
For High-Risk ANE (ANE-SS ≥5)
Initiate within 24 hours:
- High-dose methylprednisolone 30 mg/kg/day IV
- Tocilizumab (weight-based dosing: 8 mg/kg for ≥30 kg, 12 mg/kg for <30 kg)
The evidence strongly supports this combination. A 2026 study of 65 pediatric ANE patients demonstrated that combining 30 mg/kg/day methylprednisolone with tocilizumab was independently associated with reduced mortality (OR 0.04,95% CI 0.01-0.18, p<0.001) in high-risk patients 1. The mortality rate in high-risk patients dropped dramatically when this regimen was adopted, falling from 65.7% overall to 16.7% in 2024 1.
Timing is critical: Tocilizumab initiated within 24 hours correlates with good outcomes (mRS 0-2) in both high-risk (OR 11.43) and medium-risk (OR 12.80) categories 2. A systematic review confirmed that initiation within 24 hours was independently associated with good outcomes (aOR 8.60, p=0.04) 3.
For Low to Medium-Risk ANE (ANE-SS <5)
Start with:
- Methylprednisolone 20-30 mg/kg/day IV
- Consider adding IVIG if no improvement after initial treatment cycle
Both 20 and 30 mg/kg/day methylprednisolone regimens were effective in this population 1. The meta-analysis confirmed that early high-dose IV methylprednisolone (within 24 hours) is effective, with no additional benefit from adding IVIG to early steroids 4.
Role of PLEX and IVIG
When to Use PLEX
PLEX should be considered as:
- Second-line therapy after steroids fail to show improvement
- First-line in specific situations: severe hyponatremia, high thromboembolic risk (cancer, smoking, hypertension, diabetes), or associated demyelination 5
Important caveat: In the ANE-specific literature, no significant survival benefit was observed with PLEX treatment 1. However, a meta-analysis showed PLEX improved survival in general 4, and in anti-NMDAR encephalitis (a related condition), TPE was significantly more effective than IVIG 6.
PLEX consists of 5-10 sessions every other day 5. Major limitations include bleeding risk, volume shifts (problematic in dysautonomic patients), need for central line placement, and unsuitability for agitated patients 5.
When to Use IVIG
IVIG is appropriate as:
- First-line alternative when steroids are contraindicated
- Preferred in agitated patients and those with bleeding disorders 5
- Sequential add-on if no improvement after initial steroid cycle
The evidence for IVIG in ANE specifically is weak—there was no significant difference between patients treated with and without IVIG in meta-analysis 4.
Why Tocilizumab Works in ANE
ANE is characterized by cytokine storm with elevated IL-6 levels 1. Tocilizumab blocks the IL-6 receptor, directly targeting this pathophysiology. Multiple recent studies demonstrate:
- Reduced mortality when combined with high-dose steroids 1
- Improved long-term outcomes (WeeFIM scores) when given within 24 hours 7
- No reported adverse events in ANE patients 2, 3
- Independent association with reduced mortality (aOR 7.95) 3
Critical Pitfalls to Avoid
Delayed treatment: The therapeutic window is narrow. Tocilizumab efficacy drops dramatically after 72 hours 2, 3
Underdosing steroids: Use 30 mg/kg/day methylprednisolone in high-risk patients, not lower doses 1
Using IVIG alone in severe cases: IVIG monotherapy is insufficient for high-risk ANE 1, 4
Waiting for antibody results: Start immunotherapy immediately based on clinical and radiographic findings (bilateral thalamic lesions) 5
Choosing PLEX first-line inappropriately: Unless specific contraindications to steroids exist or demyelination is present, steroids ± tocilizumab should be first-line 5, 1
Guideline Context
While the 2021 autoimmune encephalitis guidelines 5 recommend starting with high-dose corticosteroids (or IVIG/PLEX if contraindicated), they note that tocilizumab should only be considered after conventional second-line therapies fail, with "minimal evidence" to support its use 5. However, this guidance predates the recent ANE-specific evidence 1, 2, 3 showing dramatic mortality reduction with early tocilizumab in high-risk ANE. The guidelines do support combination first-line therapy in severe presentations 5, which aligns with the ANE-specific data.
For general autoimmune encephalitis, the guidelines appropriately recommend sequential therapy (adding IVIG or PLEX if steroids fail) 5. But ANE represents a specific, hyperacute, cytokine-driven subtype where early aggressive combination therapy appears superior based on the most recent evidence.